An Integrative Multi-Omic Characterization of Head and Neck Carcinogenesis, Progression and Recurrence
NCT06420219
Recruiting
This study evaluates the cell and biomarkers associated with the aggressive behavior of cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/07/2025
Locations: USC / Norris Comprehensive Cancer Center, Los Angeles, California
Conditions: Head and Neck Carcinoma
Register for Updates
CardiAMP Heart Failure II Trial for Patients With Ischemic Heart Failure With Reduced Ejection Fraction
NCT06258447
Recruiting
Concentrated autologous bone marrow mononuclear cells (ABM MNC) contain potentially therapeutic cell factors and past studies support therapeutic benefit to patients with cardiac diseases of acute myocardial infarction, ischemia, and heart failure when utilized as this study is designed. The purpose of the study is to determine the safety and efficacy of CardiAMP cell therapy system in patients with ischemic heart failure. It is a prospective, multi-center, randomized, controlled, patient and ev... Read More
Gender:
ALL
Ages:
Between 21 years and 80 years
Trial Updated:
08/07/2025
Locations: Morton Plant Hospital - BayCare, Clearwater, Florida +4 locations
Conditions: Ischemic Heart Failure
Register for Updates
A Study of Valemetostat Tosylate Plus Pembrolizumab Versus Pembrolizumab Alone in First-Line NSCLC Without Actionable Genomic Alterations
NCT06644768
Recruiting
This study will compare Valemetostat Tosylate Plus Pembrolizumab vs Pembrolizumab Alone in First-line NSCLC Without Actionable Genomic Alterations
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/07/2025
Locations: University of California San Diego (Ucsd)-Moores Cancer Center, La Jolla, California +44 locations
Conditions: Non-small Cell Lung Cancer, Lung Cancer
Register for Updates
Pembrolizumab With Androgen Deprivation Therapy and Radiotherapy for the Treatment of Patients With High Risk Localized Prostate Cancer
NCT06528210
Recruiting
This phase II trial tests how well pembrolizumab along with standard of care androgen deprivation therapy, with bicalutamide and gonadotropin releasing hormone agonist, and radiotherapy for the treatment of patients with high risk prostate cancer that has not spread to other parts of the body (localized). A monoclonal antibody, such as pembrolizumab, is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Bic... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
08/07/2025
Locations: OHSU Knight Cancer Institute, Portland, Oregon
Conditions: High Risk Prostate Carcinoma, Localized Prostate Adenocarcinoma, Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8
Register for Updates
Mifepristone vs Misoprostol
NCT06502158
Recruiting
The Investigator team hypothesizes that in a randomized trial comparing mifepristone-alone or misoprostol-alone for cervical preparation for procedural abortions at 12 to 16 weeks in hospital-based care, the proportion of patients who achieve successful cervical dilation will be different between the study groups.
Gender:
FEMALE
Ages:
Between 18 years and 45 years
Trial Updated:
08/07/2025
Locations: Montefiore Medical Center, Bronx, New York
Conditions: Cervical Preparation
Register for Updates
A Study to Evaluate Solrikitug in Participants With COPD (ZION)
NCT06496620
Recruiting
A Randomized, Double-blind, Placebo-controlled, Multiple Dose-Ranging Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Solrikitug in Participants with Chronic Obstructive Pulmonary Disease (COPD).
Gender:
ALL
Ages:
Between 40 years and 75 years
Trial Updated:
08/07/2025
Locations: Research Site 051, Surprise, Arizona +55 locations
Conditions: COPD
Register for Updates
Dose-Response to Resistance Exercise on Cardiovascular Health
NCT06619444
Recruiting
A large body of evidence indicates numerous health benefits of physical activity, including prevention of cardiovascular disease (CVD), the leading cause of death in the US. This evidence has led to US Physical Activity Guidelines that recommend ≥150 min/week of moderate or ≥75 min/week of vigorous aerobic exercise (AE), plus resistance exercise (RE; such as weight lifting) on ≥2 days/week. To date, current research has mostly focused on AE, and we know a great deal about the dose-response relat... Read More
Gender:
ALL
Ages:
40 years and above
Trial Updated:
08/07/2025
Locations: Physical Activity Research Center (PARC), Pittsburgh, Pennsylvania
Conditions: Cardiovascular Risk
Register for Updates
A Study to Test the Safety and Effects of Inhaled GDC-6988 in Participants With Muco-Obstructive Disease
NCT06603246
Recruiting
This study evaluates the safety, tolerability, and activity of inhaled GDC-6988 in participants with muco-obstructive disease.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/07/2025
Locations: Accel Research Site - Achieve - Birmingham - ERN - PPDS, Vestavia Hills, Alabama +2 locations
Conditions: Non Cystic Fibrosis Bronchiectasis, Chronic Obstructive Pulmonary Disease
Register for Updates
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Non-squamous NSCLC
NCT06627647
Recruiting
The purpose of ARTEMIDE-Lung03 is to evaluate the efficacy and safety of rilvegostomig compared to pembrolizumab, both in combination with platinum-based doublet chemotherapy, as a first-line treatment of patients with non-squamous mNSCLC whose tumors express PD-L1.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/07/2025
Locations: Research Site, Mobile, Alabama +275 locations
Conditions: Non-squamous Non-small Cell Lung Cancer
Register for Updates
Social Facilitation of Alcohol Effects and Alcohol Misuse in Young Adults
NCT06627803
Recruiting
The purpose of this study is to understand social contexts and alcohol use. We hope to learn how being around peers affects alcohol consumption in young adults. About 200 young adults who drink alcohol frequently will take part in the study. This research is being funded by the National Institute on Alcohol Abuse and Alcoholism (NIAAA). Participation involves one in-person screening session with a same-sex platonic friend. Then participants will complete four in-person laboratory sessions where... Read More
Gender:
ALL
Ages:
Between 21 years and 28 years
Trial Updated:
08/07/2025
Locations: University of Southern California, Los Angeles, California
Conditions: Alcohol Consumption, Alcohol Abuse/Dependence
Register for Updates
A Study to Test Whether BI 3032950 Helps People With Ulcerative Colitis
NCT06636656
Recruiting
Adults between 18 and 80 years of age with ulcerative colitis can participate in this study. This is a study for people for whom previous treatment was not successful or who stopped previous treatment. The purpose of this study is to find out whether BI 3032950 helps people with ulcerative colitis. This study has 2 parts. In Part A, participants get BI 3032950 as an infusion into a vein every 4 weeks. After 12 weeks, doctors check whether the signs and symptoms of ulcerative colitis have improv... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
08/07/2025
Locations: Peak Gastroenterology Associates, Colorado Springs, Colorado +50 locations
Conditions: Ulcerative Colitis
Register for Updates
Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.
NCT06590857
Recruiting
Phase 1b/2 open-label trial of 225Ac-DOTATATE (RYZ101) in subjects with ER+, HER2-negative unresectable or metastatic breast cancer expressing SSTRs.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/07/2025
Locations: Research Facility, Phoenix, Arizona +22 locations
Conditions: Metastatic Breast Cancer, HER2-negative Breast Cancer, ER+ Breast Cancer, Advanced Breast Cancer
Register for Updates